“Advancements in RNAi Therapies and Precision Medicine Driving Market Growth”
- A significant and accelerating trend in the global hyperoxaluria drug market is the rapid adoption of RNA interference (RNAi) therapies and precision medicine approaches, which are transforming treatment paradigms by targeting the genetic root causes of the disease
- For instance, lumasiran and nedosiran have emerged as pioneering RNAi-based drugs that effectively reduce oxalate production, offering patients safer and more targeted options compared to conventional treatments
- RNAi therapies enable personalized treatment regimens based on specific gene mutations such as AGXT and GRHPR, enhancing therapeutic outcomes and minimizing adverse effects. Complementary approaches including enzyme replacement therapies and small molecule inhibitors are also gaining traction
- The integration of genetic testing and companion diagnostics into clinical practice is facilitating earlier diagnosis and better patient stratification, supporting more precise treatment decisions
- Companies such as Alnylam Pharmaceuticals and Dicerna Therapeutics are leading innovation by advancing next-generation therapies that leverage gene silencing and enzyme modulation technologies
- The demand for hyperoxaluria drugs that offer targeted, effective, and safer treatment options is growing rapidly across both developed and emerging markets, as patients and healthcare providers increasingly focus on long-term disease management and improved quality of life
